Protection from lethal Lassa disease can be achieved both before and after virus exposure by administration of single-cycle replicating Lassa virus replicon particles.

Lassa fever is a frequently severe human disease that is endemic to several countries in West Africa. To date, no licensed vaccines are available to prevent Lassa virus (LASV) infection, even though Lassa fever is thought to be an important disease contributing to mortality and both acute and chronic morbidity. We have previously described a vaccine candidate composed of single-cycle LASV replicon particles (VRPs) and a stable cell line for their production. Here, we refine the genetic composition of the VRPs and demonstrate the ability to reproducibly purify them with high yields. Studies in the guinea pig model confirm efficacy of the vaccine candidate, demonstrate that single-cycle replication is necessary for complete protection by the VRP vaccine, and show that post-exposure vaccination can confer protection from lethal outcome.

[1]  S. Finke,et al.  Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter , 1999, Journal of Virology.

[2]  A. García-Sastre,et al.  Differential Inhibition of Type I Interferon Induction by Arenavirus Nucleoproteins , 2007, Journal of Virology.

[3]  J. McCormick,et al.  Clinical virology of Lassa fever in hospitalized patients. , 1987, The Journal of infectious diseases.

[4]  Donald S. Grant,et al.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.

[5]  J. McCormick,et al.  Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. , 1991, The Journal of general virology.

[6]  P. Jahrling,et al.  Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  T. Bell,et al.  Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques , 2018, mBio.

[8]  J. McCormick,et al.  Acute sensorineural deafness in Lassa fever. , 1990, JAMA.

[9]  M. Salvato,et al.  Improving the Breadth of the Host’s Immune Response to Lassa Virus , 2018, Pathogens.

[10]  J. C. de la Torre,et al.  General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines , 2015, Journal of Virology.

[11]  Pardis C Sabeti,et al.  Lassa Fever in Post-Conflict Sierra Leone , 2014, PLoS neglected tropical diseases.

[12]  M. Bachmann,et al.  Major findings and recent advances in virus-like particle (VLP)-based vaccines. , 2017, Seminars in immunology.

[13]  J. Kuhn,et al.  Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus) , 2018, Journal of Infectious Diseases.

[14]  Erica Ollmann Saphire,et al.  Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression , 2011, Proceedings of the National Academy of Sciences.

[15]  J. Klena,et al.  Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model , 2018, The Journal of infectious diseases.

[16]  H. Ly,et al.  Cap binding and immune evasion revealed by Lassa nucleoprotein structure , 2010, Nature.

[17]  Donald S. Grant,et al.  Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. , 2016, Antiviral research.

[18]  I. Lukashevich,et al.  A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. , 2007, Vaccine.

[19]  T. Ksiazek,et al.  Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. , 2001, Vector borne and zoonotic diseases.

[20]  S. Hallam,et al.  Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development , 2018, npj Vaccines.

[21]  T. Monath,et al.  Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. , 1974, The American journal of tropical medicine and hygiene.

[22]  E. S. Smith,et al.  A prospective study of the epidemiology and ecology of Lassa fever. , 1987, The Journal of infectious diseases.

[23]  S. Paessler,et al.  Lassa fever–induced sensorineural hearing loss: A neglected public health and social burden , 2018, PLoS neglected tropical diseases.

[24]  D. Safronetz,et al.  Current research for a vaccine against Lassa hemorrhagic fever virus , 2018, Drug design, development and therapy.

[25]  J. McCormick,et al.  Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys , 1992, Journal of medical virology.

[26]  N. Wauquier,et al.  Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection , 2015, Journal of Virology.

[27]  S. Nichol,et al.  Efficient Rescue of Recombinant Lassa Virus Reveals the Influence of S Segment Noncoding Regions on Virus Replication and Virulence , 2011, Journal of Virology.

[28]  M. Wolfe,et al.  Historical Lassa Fever Reports and 30-year Clinical Update , 2006, Emerging infectious diseases.

[29]  D. E. Carey,et al.  An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report. , 1970, The American journal of tropical medicine and hygiene.